- LexaGene (LXG) and its MiQLab System is set to sell to a veterinary hospital in Wisconsin
- LexaGene is a molecular diagnostics company that has made the MiQLab System for automated, multiplexing PCR-based syndromic testing in veterinary clinics
- The company now has MiQLab Systems operating in 10 states across America
- People who use the system simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press ‘go’.
- LexaGene Holdings, Inc. (LXG) is down 3.12 per cent, trading at C$0.16 at 9:30 am EST
LexaGene Holdings, Inc. (LXG) has entered into a purchase agreement with a veterinary hospital in Wisconsin.
LexaGene is a molecular diagnostics company that has made the MiQLab System for automated, multiplexing PCR-based syndromic testing in veterinary clinics.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated,
“Once we complete our scheduled installations, we will have MiQLab Systems operating in 10 states across the US. Since the start of this year, our install base has increased 240 per cent and we expect an even steeper increase in the latter part of this year.”
LexaGene develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
People who use the system simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press ‘go’.
The MiQLab system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours.
The open-access feature is designed for custom testing. People can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
LexaGene Holdings, Inc. (LXG) is down 3.12 per cent, trading at C$0.16 at 9:30 am EST.
